Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 22Thoracic 21Gastrointestinal 9Breast 4Lymphoid 2Genitourinary 2CNS 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Gliosarcoma 22Glioblastoma 22Brain Neoplasms 16Glioma 10Astrocytoma 9Oligodendroglioma 8Central Nervous System Neoplasms 7Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Medulloblastoma 2Gastrointestinal Stromal Tumors 2Esthesioneuroblastoma, Olfactory 2Esophageal Neoplasms 2Ependymoma 2Colonic Neoplasms 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 17pembrolizumab 12Doxorubicin 10fludarabine 7Irinotecan 7Blood Specimen Collection 7Temozolomide 6Gemcitabine 6Etoposide 6Radiotherapy 5Ifosfamide 5Carboplatin 5Albumin-Bound Paclitaxel 5tecogalan 4cemiplimab 4Vincristine 4Trabectedin 4Paclitaxel 4Nivolumab 4Filgrastim 4Drug Therapy 4Dexamethasone 4Bevacizumab 4pazopanib 3olaparib 3nilotinib 3dostarlimab 3aflibercept 3Therapeutics 3Taxes 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Erlotinib Hydrochloride × Sarcoma × Clear all
NCT00603356 2011-09-27

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGynecologicOther solid neoplasmSarcomaThoracic

Mesothelioma, Neoplasms, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡